Revised Annual Secretarial Report for the year ended 31.03.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Ltd has filed a revised Annual Secretarial Compliance Report for FY 2024-25 with BSE, as required under SEBI LODR Regulation 24A. The report, prepared by M/s Anil Negi & Company (Practicing Company Secretaries), confirms overall compliance with applicable SEBI regulations, circulars, and secretarial standards. One non-compliance was flagged: a delay in submitting the Share Capital Audit Reconciliation Report under Regulation 76 of SEBI (Depositories & Participants) Regulations, 2018 for the quarters ended June and September 2024, which the company has since rectified. The statutory auditor resigned on August 14, 2024 (within 45 days of the June quarter end) after issuing the limited review report. No actions were taken by SEBI or stock exchanges against the company, its promoters, directors, or subsidiaries.
This is a routine annual compliance filing with no material impact on shareholders. The flagged delay in share capital audit reconciliation for two quarters in 2024 is procedural and has since been corrected, unlikely to move the stock. The August 2024 auditor resignation is a minor governance event but was handled within SEBI's framework.